CagriSema Explained: The GLP-1 + Amylin Combination That May Outperform Wegovy
If semaglutide was the first wave and tirzepatide was the second, CagriSema is the third — and it may be the most potent yet. Novo Nordisk’s combination of semaglutide (a GLP-1 receptor agonist) with cagrilintide (a long-acting amylin analog) has filed for FDA approval and represents the next evolution in metabolic peptide therapy.
This guide covers what CagriSema is, how it works, what the clinical data shows, and how it compares to existing GLP-1 medications.
What Is CagriSema?
CagriSema is a fixed-ratio combination of two peptides in a single once-weekly injection:
- Semaglutide — a GLP-1 receptor agonist (the active ingredient in Ozempic and Wegovy)
- Cagrilintide — a long-acting analog of amylin, a hormone co-secreted with insulin that regulates appetite, gastric emptying, and glucagon secretion
The dual-hormone approach targets appetite and metabolism through two distinct pathways simultaneously. GLP-1 acts primarily in the brain’s appetite centers and on gastric emptying. Amylin provides complementary appetite suppression and glucagon regulation that GLP-1 alone doesn’t fully address.
How It Differs From Existing GLP-1s
| Feature | CagriSema | Semaglutide (Wegovy) | Tirzepatide (Zepbound) |
|---|---|---|---|
| Targets | GLP-1 + Amylin receptors | GLP-1 receptor only | GLP-1 + GIP receptors |
| Administration | Weekly injection | Weekly injection | Weekly injection |
| Weight Loss | ~20-25% (Phase 3 data) | ~15-17% | ~18-22% |
| Manufacturer | Novo Nordisk | Novo Nordisk | Eli Lilly |
| FDA Status | Filed for approval (2026) | Approved (2021) | Approved (2023) |
Clinical Trial Data
CagriSema’s Phase 3 trial data has been compelling. The REDEFINE program showed weight loss in the range of 20-25% — substantially more than semaglutide alone and competitive with tirzepatide at the highest doses. If the FDA approves CagriSema at the efficacy levels seen in trials, it would become the most potent single-injection weight loss therapy available.
The amylin component adds a layer of metabolic regulation that goes beyond appetite suppression. Amylin analogs:
- Reduce post-meal glucagon secretion (lowering blood sugar spikes)
- Slow gastric emptying through a complementary pathway to GLP-1
- Act on area postrema in the brainstem for additional satiety signaling
- May improve insulin sensitivity independently of weight loss
What This Means for the Research Peptide Market
CagriSema represents a trend toward combination peptide therapies — multiple peptides targeting complementary pathways in a single preparation. This same principle applies to the research peptide space, where stacking protocols (like BPC-157 + TB-500 for recovery, or CJC-1295 + Ipamorelin for GH optimization) have been popular for years.
As the pharmaceutical industry validates the concept of multi-peptide combinations, it indirectly validates the approach that the research community has been exploring. Research-grade semaglutide and tirzepatide remain available from verified suppliers for laboratory purposes.
GLP-1 Research Lab
GLP-1 SpecialistDedicated GLP-1 peptide supplier with verified Semaglutide and Tirzepatide.
Shop GLP-1s →BioPure Peptides
Code: POWERSemaglutide, Tirzepatide, Retatrutide — all three major GLP-1 research peptides. Third-party tested.
Shop Semaglutide →Shop Retatrutide →Apollo Peptide Sciences
Verified COAsSemaglutide and Tirzepatide with independent testing and Refersion tracking.
Shop Apollo →Frequently Asked Questions
Related Articles
Not Sure Which Peptide Is Right for You?
Take our free 60-second quiz and get personalized recommendations based on your goals.
Take the Quiz →